AbbVie (ABBV) Stock Forecast & Price Target

AbbVie has demonstrated a robust financial outlook, as evidenced by management's updated FY 2025 guidance, which includes an increase in non-GAAP EPS guidance to $12.09-$12.29 and revenue expectations now set at approximately $59.7 billion, reflecting a modest increase of $700 million. The company's recent quarterly performance exceeded expectations in both sales and quarterly EPS, signifying continued strong commercial traction. Additionally, positive developments in clinical data for Rinvoq have further solidified its market position, contributing to the optimistic growth narrative driven by key products like Skyrizi and Rinvoq.

AbbVie faces significant downside risks stemming from disappointing commercial execution across key products, including Skyrizi, Rinvoq, and Botox, which could impede revenue growth in its portfolio. The reliance on the Aesthetics business, which accounted for approximately 9.2% of sales in FY 2024, is particularly concerning amid ongoing macroeconomic challenges that may adversely affect discretionary consumer spending. Furthermore, projected sales for Rinvoq indicate a potential decline approaching $15 billion, with expectations of reduced top-line performance post-2033 intensifying concerns about AbbVie’s future revenue stability.